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บทคดัยอ่  
วตัถปุระสงค์: เพื่อประมาณประสิทธิภาพของยากลุ่มบิสฟอสโฟเนตในการ
ป้องกนักระดูกหกัจากโรคกระดกูพรุนในหญงิวยัหมดประจ าเดอืนโดยวธิทีบทวน
วรรณกรรมอย่างเป็นระบบและการวิเคราะห์อภิมาน วิธีการศึกษา: สืบค้น
งานวจิยัจากฐานขอ้มูลอเิล็กทรอนิกส์ ไดแ้ก่  MEDLINE และ Cochrane Library 
ตัง้แต่เริ่มมีฐานข้อมูลจนถึงเดือนพฤศจิกายน 2558 โดยคดัเลือกงานวิจยัเชิง
ทดลองแบบสุ่มที่มีกลุ่มควบคุมที่ศึกษาประสิทธผิลของยากลุ่มบิสฟอสโฟเนต 
( alendronate, clodronate, etidronate ibandronate, risedronate แ ล ะ 
zolendronate) เปรียบเทียบกับการได้รบัยาหลอกและ/หรือการให้แคลเซียม
รว่มกบัวติามนิด ีและวดัอุบตักิารณ์การเกดิกระดกูหกั ผลการศึกษา: จากการสบื
คน้พบงานวจิยัทีผ่า่นเกณฑก์ารคดัเลอืก 16 ฉบบั  ศกึษาผลของยาเป็นเวลา 1 - 3 
ปี การใหย้า alendronate (5 - 10 มก.ตอ่วนั) และการใหย้า risedronate (2.5 และ 
5 มก.ต่อวนั) ช่วยป้องกนัการเกิดกระดูกสนัหลงัหกัได้ร้อยละ 45 (RR = 0.55; 
95% CI: 0.46, 0.67) และรอ้ยละ 38 (RR = 0.62; 95% CI: 0.51, 0.75) ตามล าดบั 
ส่วนประสทิธผิลในการป้องกนัการเกดิกระดูกที่มใิช่กระดูกสนัหลงัหกัพบว่า ยา 
alendronate, risedronate และ zoledronate (5 มิลลิกร ัมต่อ ปี) ช่วยป้องกัน
กระดูกหกัได้ร้อยละ 15 (RR = 0.85; 95% CI: 0.75, 0.97), ร้อยละ 19 (RR = 
0.81; 95% CI: 0.72, 0.90) และร้อยละ 24 (RR = 0.76; 95% CI: 0.66, 0.88) 
ตามล าดบั ทัง้นี้ยา clodronate, etidronate และ ibandronate ยงัมขีอ้มลูงานวจิยัที่
จ ากดั และยงัพบว่ายากลุ่มบิสฟอสโฟเนตช่วยป้องกนัการเกิดกระดูกหกัได้ทัง้
บรเิวณกระดกูสนัหลงั (RR = 0.57; 95% CI: 0.50,0.64) และบรเิวณทีม่ใิช่กระดูก
สนัหลงั (RR = 0.81 ; 95% CI: 0.76,0.87) ไดอ้ย่างมนีัยส าคญัทางสถติเิมือ่เทยีบ
กบักลุ่มควบคุม  สรุป: ผลการศึกษาที่ได้เป็นหลกัฐานเชิงประจกัษ์ที่สนับสนุน
ประสทิธผิลของยากลุ่มบสิฟอสโฟเนตในการป้องกนัการเกิดกระดูกหกัจากโรค
กระดูกพรุนในหญิงวัยหมดประจ าเดือนได้ อย่างไรก็ตาม ยา clodronate, 
etidronate และ ibandronate  ยงัมขี้อมูลจากการศึกษาไม่มากพอ จงึควรศึกษา
เพิม่เตมิตอ่ไป  
ค าส าคญั: ประสทิธภิาพ, กระดูกหกั, โรคกระดกูพรุน, หญงิวยัหมดประจ าเดอืน, 
ยากลุม่บสิฟอสโฟเนต  
 
 
 
Abstract 
Objective:  To estimate the efficacy of bisphosphonates in preventing 
osteoporotic fractures in postmenopausal women systematic review and 
meta- analysis.  Methods:  Published reports were searched through 
electronic database including MEDLINE and the Cochrane Library from 
inception to November 2015.  We selected randomized controlled trials 
( RCTs)  examining efficacy of bisphosphonates compared with placebo 
and/ or calcium plus vitamin D with outcomes of incidence of bone fracture. 
Results: Sixteen RCTs with duration of 1 – 3 years met the eligibility criteria. 
Meta-analysis showed that alendronate (5 - 10 mg/day) and risedronate (2.5 
and 5 mg/day) could prevent vertebral fracture by 45% (RR = 0.55; 95% CI: 
0 .46 , 0.67)  and 38% (RR = 0 .62 ; 95% CI:  0 .51 , 0.75) , respectively. 
Alendronate, risedronate and zoledronate ( 5 mg/ day)  could prevent non-
vertebral fractures by 15% (RR = 85; 95% CI: 0.75, 0.97), 19% (RR = 0.81; 
95%  CI:  0. 72, 0. 90)  and 24%  ( RR =  0. 76; 95%  CI:  0. 66, 0. 88) , 
respectively.There were a limited number of studies on clodronate, etidronate 
and ibandronate.  All bisphosphonates combined could significantly prevent 
vertebral fracture (RR = 0.57; 95% CI: 0.50, 0.64) and non-vertebral fracture 
(RR =  0. 81; 95% CI:  0. 76, 0. 87) .  Conclusion:  Bisphosphonates were 
efficacious in preventing bone fractures in postmenopausal women with 
osteoporosis.  However, studies on clodronate, etidronate and ibandronate 
were limited, thus further studies should be conducted.   
Keywords:  efficacy, fracture, osteoporosis, postmenopausal, 
bisphosphonate   
 
 
 
 
   
Introduction 
Osteoporosis is an abnormality of which bone mineral 
density is decreased leading to a decrease in bone strength 
and finally an increase in risk of bone fracture especially 
vertebra, hip and wrist.1 World Health Organization estimated 
that there were 75 patients with osteoporosis in Europe, North 
America and Asia combined.  Of all osteoporosis patients 
Editorial note 
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worldwide, 9 million of them would progress to bone fractures 
annually. 2  Bone fractures associated with osteoporosis is a 
cause of disability and high healthcare expenditure. In the US, 
the expense for osteoporosis treatment is as high as 18 billion 
dollars annually. 3 Osteoporosis related bone fractures also 
impair quality of life and increase a risk of mortality in the 
elderly. 4 Postmenopausal women have a higher risk of 
osteoporosis than other age groups with age-adjusted risk of 
289 per 100,000 women and 114 per 100,000 men.5  
The treatment for osteoporosis is targeting at reducing the 
risk of various bone fractures.  There have been several 
medications for preventing bone fractures.  Bisphosphonates 
are first- line therapy for postmenopausal women with 
osteoporosis recommended by the clinical practice guideline 
of the Royal College of Orthopaedic Surgeons of Thailand and 
Thai Osteoporosis Foundation. 5- 7 Bisphosphonates have 
bone-mineral balance effect, cellular effect, and inhibition of 
aggregation, hydroxyapatite breakdown and bone resorption. 
These effects lead to an increase in bone mineral density.8  
There have been randomized controlled trial (RCT) studies 
on efficacy of bisphosphonate drugs with various results. Few 
meta-analysis studies have been conducted but probably with 
some shortcomings such as diverse populations, outcomes, 
and comparator interventions. 9,10 However, there has been a 
relative lack of meta-analysis studies with conclusive results 
of bisphosphonate drugs for preventing bone fractures in 
postmenopausal women with osteoporosis.  
In this present study, we aimed to examine the efficacy of 
bisphosphonate drugs in preventing bone fractures both 
vertebral and non- vertebral in postmenopausal women with 
osteoporosis by means of systematic review and meta-
analysis. The findings could be useful for selecting the optimal 
drug treatment in postmenopausal women with osteoporosis.  
     
Methods 
 
 In this systematic literature review and meta- analysis 
study, we selected randomized controlled trials (RCTs)  to 
examine efficacy of bisphosphonate drugs including 
alendronate, clodronate, etidronate ibandronate, risedronate 
and zolendronate in preventing bone fractures both vertebral 
and non- vertebral.  Comparators could be placebo and/ or 
calcium plus vitamin D as an active control.  Patients were 
limited to postmenopausal women with osteoporosis.  
  
Database and data searching    
Two databases namely Pubmed and the Cochrane Library 
were searched for relevant records from inception up to 
November 2015.  We used the Medical Subject Headings 
(MeSH) of "Osteoporosis," " Osteoporosis, Postmenopausal," 
"Fractures, Bone,"  and "Diphosphonates"  and key words of 
alendronate, clodronate, etidronate, ibandronate, risedronate 
and zolendronate with conjunction operators of “and” and “or.” 
We also searched for additional RCT studies cited in 
systematic review papers and clinical research papers.  
 
Selection and quality evaluation of RCT studies  
Records of studies were independently searched by two 
investigators ( WA, SS)  based on inclusion and exclusion 
criteria.  If any disagreement, a third opinion from the third 
investigator (WB)  was obtained to form the conclusion.  To 
meet with the inclusion criteria, studies had to be RCT 
randomized controlled trial ( RCT)  examining efficacy of 
bisphosphonate drugs including alendronate, clodronate, 
etidronate, ibandronate, risedronate and zolendronate.  The 
comparators could be placebo and/ or calcium plus vitamin D 
as an active control.  The studies had to have outcomes of 
bone fracture, either vertebral and/ or non- vertebral.  The 
studies had to be in English language.  Cost- effectiveness 
studies and those unavailable for full data access were 
excluded.  
The selected articles of studies were examined for quality 
using the Maastricht-Amsterdam scale.11 The use of the scale 
helped assure the internal validity of our study.  The scale 
measures bias in 11 aspects as follows:  ( 1)  adequate 
randomization, ( 2)  concealed treatment allocation, ( 3) 
comparable baseline characteristics, (4) interventions blinded 
to patients, (5)  interventions blinded to care providers, (6) 
interventions blinded to outcome assessors, ( 7)  co-
interventions avoided or similar, (8) compliance acceptable in 
all groups, (9)  drop-out rate described and acceptable, (10) 
similar time of outcome assessment in all groups, and (11) 
intention- to- treat analysis included.  For each statement, 1 
point is awarded for “yes” and 0 for “no” or “unsure.” A given 
article with a score of 6 points or higher was considered a 
high quality study; while one with a score of lower than 6 
points a low quality study.  Studies with low quality had a 
higher risk of bias. However, both high and low quality studies 
were included in meta-analysis.  Two investigators performed 
study quality evaluation independently and the third 
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investigator was asked for opinion if any disagreement 
between the first two investigators.  
 
Data extraction  
Data from individual selected RCTs were extracted as 
follows:  interventions, authors, year of publication, study 
duration, age and number of participants, study setting, 
interventions, and quality of study.  
 
Data synthesis and summary   
In this meta- analysis, for given indications namely ( 1) 
prevention of vertebral fractures and (2)  prevention of non-
vertebral fractures, at least two studies for each 
bisphosphonate were required to determine pooled efficacy of 
the drug. Meta-analysis of all bisphosphonate drugs combined 
for each of the two indications was also performed.  
Once summarized, pooled results of the risk ratio (RR) of 
incidence of the fractures were estimated with 95% confidence 
interval (95% CI)  in the form of Forest’s plot.  Based on the 
effect size estimate of Hedges & Olkin, test of heterogeneity 
( or differences between studies)  was used to select method 
of pooling.  If significant heterogeneity was not found among 
studies, fixed effects model was used for pooling the 
outcomes; if found, a random effect model was used. The test 
of heterogeneity among RCTs was based on Q statistics12 with 
a significance level ( )  of 0. 10 and percentage of 
inconsistency index (I2). In pooling the outcomes, if I2 was ≤ 
25, no heterogeneity was found and fixed effect model was 
chosen.  If I2 was > 25% , significant heterogeneity was 
indicated and random effect model was chosen. 12 Analysis 
was performed using Review Manager® ( Revman version 
5.3.5). 
 
Results  
A total of 2,250 records of studies on bisphosphonates 
were found.  Once duplicate studies were excluded and 
inclusion and exclusion criteria were applied, a total of 16 
articles of 16 studies were retained with the most studies of 
risedronate (6 studies) , followed by alendronate (4 studies) , 
etidronate and zolendronate (2 studies each), and clodronate 
and ibandronate (1 study each) (Figure 1). 
 
 
 Figure 1  Flow diagram of literature search and study 
selection. 
 
Of all the 16 studies selected, the largest study had 7,765 
patients and the smallest had 54 patients.  Majority of the 
studies were from Europe ( 10 of 16 studies) , followed by 
America (5 studies) , and others.  In these studies, dosage 
regimens and duration of treatment were different.  All 16 
students had high quality based on Maastricht-Amsterdam 
scale (score of 6 points or higher)11 (Table 1).  
 
Efficacy of bisphosphonates in reducing the risk of 
vertebral fractures compared with controls  
Meta-analysis indicated that alendronate 5 –  10 mg/ day 
and risedronate 2. 5 and 5 mg/ day could significantly reduce 
the risk of vertebral fractures by 45% (RR =  0. 55; 95%CI: 
0. 46, 0. 67)  and 38% (RR =  0. 62; 95%CI:  0. 51, 0. 75) , 
respectively (Figures 2 and 3) .  In the study of Liberman13, 
alendronate 5 -  10 mg/ day in postmenopausal women with 
osteoporosis regardless of history of bone fractures could 
significantly reduce the risk of vertebral fractures in those with 
previous bone fracture by 48% (RR =  0. 52; 95%CI:  0. 28, 
0. 97)  but not in those with no bone fracture history (RR = 
1.90; 95%CI:  0.51, 7.00) .  In addition, since alendronate 20 
mg/ day caused significant adverse effects, the study was 
terminated prior to completion.  For zolendronate, the dose of 
5 mg per year could reduce the risk of vertebral fracture 
compared with controls but with no statistical significance (RR 
0.48; 95%CI: 0.14, 1.64) (Figure 4).  
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For the pooled efficacy of all bisphosphonates, these 
drugs could significantly reduce the risk of vertebral fractures 
in postmenopausal women with osteoporosis by 43% 
compared with controls (RR = 0.57; 95%CI: 0.55, 0.64) (Figure 
5). 
 
 
Table 1  Characteristics of selected studies (16 studies, 30,123 patients).  
Drug Authors 
Year of 
publication 
Interventions‡ 
Duration  
(yr) 
Patients  
Study setting 
Study  
quality* Age (yr) 
Number  
(test / control) 
Alandronate Liberman UA13 1995 T: 5, 10, 20 mg/d 
C: placebo + calcium  
3 45 - 80 881 
(526/355) 
Europe, Australia, 
America 
high 
Black DM14 1996 T: 5, 10 mg/d 
C: placebo + calcium + vitamin D 
2 55 – 81 2027 
(1022/1005) 
America high 
Bone HG15 1997 T: 2.5, 5 mg/d  
C: placebo + calcium 
2 60 – 85 359 
(268/91) 
Europe high 
Cumming SR16 1998 T: 5, 10 mg/d  
C: placebo + calcium + vitamin D 
4 45 - 80 4432 
(2214/2218) 
Europe high 
Clodronate McCloskey E17 2004 T: 800 mg/d  
C: placebo + calcium  
3 < 70 593 
(292/301) 
Europe high 
Etidronate Watt NB18  1990 T: 400 mg/d  
C: placebo + calcium 
2 > 75 423 
(212/211) 
America high 
Meunier PJ19 1997 T: 400 mg/round  
C: placebo + calcium 
1 45 - 57 54 
(21/16) 
Europe high 
Ibandronate Chesnut CH20 2004 T: 2.5 mg/d 
C: placebo + calcium + vitamin D 
3 55 – 80 2946 
(1964/982) 
Europe high 
Risedronate Harris ST21 1999 T: 2.5, 5 mg/d 
C: placebo + calcium + vitamin D 
3 < 85 2458 
(1638/820) 
America high 
Fogelman I22 2000 T: 2.5, 5 mg/d 
C: placebo + calcium 
2 > 80 543 
(363/180) 
Europe high 
Reginster J.-Y.23 2000 T: 2.5, 5 mg/d 
C: placebo + calcium + vitamin D 
3 > 85 1226 
(815/411) 
Europe, Australia high 
McClung MR24 2001 T: 2.5, 5 mg/d 
C: placebo + calcium + vitamin D 
3 70 - 79 5445 
(3624/1821) 
Europe, Australia, 
America 
high 
Sorensen OH25 2003 T: 5 mg/d 
C: placebo + calcium + vitamin D 
5 < 85 265 
(135/130) 
Europeย, Australia high 
Hooper MJ26 2005 T: 2.5, 5 mg/d  
C: placebo + calcium 
3 42 – 63 383 
(257/126) 
Australia high 
Zoledronate Black DM27 2007 T: 5 mg/yr 
C: placebo + calcium + vitamin D 
3 65 - 89 7765 
(3876/3889) 
America high 
Hwang JS28 2011 T: 5 mg/yr  
C: placebo + calcium + vitamin D 
2 64 - 88 323 
(163/160) 
Taiwan, Hong Kong high 
 * Study quality based on Maastricht-Amsterdam scale: high quality (≤ 6 of 11 poins), low quality (< 6 of 11 points).  
 ‡ T = test drug; C = control.  
 
 
 
 Figure 2  Efficacy of alendronate in reducing the risk of vertebral fracture compared with controls.  
Note: Liberman UA = primary prevention of vertebral fractures; Liberman UA(1) = secondary prevention of vertebral fractures.  
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 Figure 3  Efficacy of risedronate in reducing the risk of vertebral fracture compared with controls.  
 
 
 
 
 Figure 4  Efficacy of zoledronate in reducing the risk of vertebral fracture compared with controls.  
 
 
 
 
 Figure 5  Efficacy of bisphosphonates in reducing the risk of vertebral fracture compared with controls. 
 
  
Efficacy of bisphosphonates in reducing the risk of non-vertebral fractures compared with controls 
Meta-analysis suggested that alendronate 5 – 10 mg/day, 
risedronate 2. 5 and 5 mg/ day and zoledronate 5 mg/ year 
could significantly reduce the risk of non-vertebral fractures by 
15% (RR = 85; 95%CI:  0.75, 0.97)  and 19% (RR =  0.81; 
95%CI: 0.72, 0.90), and 24% (RR = 0.76; 95%CI: 0.66, 0.88), 
respectively (Figures 6 - 8).  
For the pooled efficacy of all bisphosphonates, these 
drugs could significantly reduce the risk of non- vertebral 
fractures in postmenopausal women with osteoporosis by 19% 
compared with controls (RR =  0. 8 1 ; 95%CI:  0. 7 6 , 0. 8 7 ) 
(Figure 9). 
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 Figure 6  Efficacy of alendronate in reducing the risk of non-vertebral fracture compared with controls. 
 
 
 
 Figure 7  Efficacy of risedronate in reducing the risk of non-vertebral fracture compared with controls. 
 
 
 
 Figure 8  Efficacy of zoledronate in reducing the risk of non-vertebral fracture compared with controls.  
 
 
 
 Figure 9  Efficacy of bisphosphonates in reducing the risk of non-vertebral fracture compared with controls. 
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Discussions and Conclusion  
 
In our systematic review and meta- analysis, individual 
bisphosphonates had different benefits in preventing bone 
fractures in postmenopausal women with osteoporosis. These 
could be in part due to differences in dosage regimen, drug 
administration, and duration of study among these studies.  
The efficacy of alendronate in preventing bone fractures 
was consistent with the study of Wells and colleagues29 and 
Serrano and co-workers.30 For risedronate 2.5 and 5 mg/day, 
its efficacy in preventing bone fractures, both vertebral and 
non-vertebral, found in this study was consistent with the study 
of Cranney et al where the doses of 2.5 and 5 mg/day were 
efficacious in reducing risk of vertebral and non- vertebral 
fractures, respectively.31  
The meta-analysis indicated that intravenous zoledronate 
5 mg per year could significantly reduce the risk of vertebral 
fractures but not non-vertebral ones.  Previous meta-analysis 
of Zhang and colleagues zoledronate found that intravenous 
zoledronate 5 mg per year for 1 to 6 years from 9 studies was 
significantly efficacious in reducing the risk of bone fractures 
(OR = 0.81; 95% CI = 0.76, 0.87); however, benefits specific 
to vertebral or non- vertebral fractures were not separately 
determined. 32  It was noteworthy that in the work of Zhang et 
al, a high level of heterogeneity among RCTs was found (I2 = 
94% , P- value < 0. 0001) .  On the other hand, a low level of 
heterogeneity was found in our study despite outcomes of only 
two studies were pooled ( I2 =  27% , P- value =  0. 24) .  In 
addition, while men and women were included in the study of 
Zhang et al; only women were included in our study.  This 
could contribute to a low heterogeneity in our study despite 
only two RCTs included in our study.  
Our meta-analysis study has some advantages. Since the 
analyses were on individual drugs in bisphosphonate group 
and the group as a whole, our study provided a more diverse 
and up- to-date results than previous studies.  In addition, our 
study included RCTs with high quality, therefore the pooled 
efficacy results of our meta-analysis were more reliable and 
applicable in the practice of optimal drug selection.  
Certain limitations were found in our study.  Even though 
large databases were used in our study, studies from other 
sources such as other established databases, local research 
reports submitted to the granters and proceedings from 
academic conferences could be missed.  As a result, certain 
bisphosphonates were represented by very few number of 
studies.  The addition of studies found solely in other 
databases such as Scopus, CINAHL and EMBASE should be 
strived in the future.  Sensitivity analysis and publication bias 
based on Egger’s test should be added in the future studies.  
In our systematic review on efficacy of bisphosphonates in 
preventing bone fractures from osteoporosis in 
postmenopausal women, the 16 studies included were 
different regarding studied drugs, groups of investigators, year 
of publication, interventions, duration of study, study 
population (age and number) and study setting; especially the 
doses of these bisphosphonates which ranged from 5 to 800 
mg.  This analysis was however based on high quality RCT 
studies as evaluated by Maastricht-Amsterdam scale.11  
In conclusion, three bisphosphonates namely 
alendronate, risedronate and zolendronate were confirmed for 
their efficacy in preventing bone fractures from osteoporosis 
in postmenopausal women.  Other bisphosphonates including 
clodronate, etidronate and ibandronate were inconclusive with 
limited RCT studies.  Certain bisphosphonates were 
efficacious in preventing bone fractures both vertebral and 
non-vertebral ones.  
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